This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Finding low-cost retirement plans can significantly boost your savings. Discover options that won't break the bank!
23,352 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Record first-quarter funding in defense technology heightens concerns that the defense tech boom become a bubble. Val...
Three leading egg producers settle with federal and state regulators over alleged price‑fixing, donating 53 million e...
Greg Abel is stepping into Warren Buffett’s shoes with a plan that could redefine Berkshire Hathaway’s approach. This...
As AI infrastructure expands beyond GPUs, investors ask whether Nvidia is undervalued or overvalued — or perhaps both...
coca-cola just all-time high marks a moment of momentum for KO, while PepsiCo sits below its peak with a different ri...
President Trump asserted Walmart trimmed prices at the administration's request to celebrate the 250th birthday, but ...
HYSA interest is taxed as ordinary income in the year it is credited, not when you spend it. There are no special rat...
Broadcom inks a long-term extension with Apple through 2031, tying roughly 20% of AVGO's annual sales to the iPhone m...
A Wisconsin criminal complaint against Circle raises urgent questions about how USDC freezes are enforced and whether...
Wyoming officials trace rare bacteria found in Cheyenne wastewater back to Meta’s Cosmo data center project, promptin...
For the first time ever, Citi Wealth notes a surge in ultrawealthy U.S. clients seeking cross-border diversification ...